Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 256

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 256
---
 consolidated financial statements as described in Note 3.
 
Active ingredient
 
The Active ingredient segment involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan, oat oil and avenanthramides. These and similar manufactured products are sold primarily through distribution networks.
 
Biopharmaceutical
 
The Biopharmaceutical segment includes the results of Aeterna Zentaris from its acquisition on June 3, 2024 (Note 5). The segment involves the commercializing and developing pharmaceutical therapeutics and diagnostic tests, including the Company’s lead product, Macrilen® (macimorelin). The segment also includes costs associated with the development of our pre-clinical pipeline to potentially address unmet medical needs across several indications with a focus on rare or orphan indications.

F-42
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 
The table below summarizes the relevant financial information by operating segment:
 
Summary relevant financial information by operating segment
 
                                                                   Year                                                                          
                                                                   ended December 31, 2024                                                       
                                                                   Active ingredient               Pharmaceutical                Total           
                                                                   $                               $                             $               
Revenue                                                                          8,492                         1,095                    9,587    
Cost of sales                                                                   (4,706   )                      (152   )               (4,858   )
Gross margin                                                                     3,786             943                                  4,729    
Research and development                                                        (3,943   )                    (4,361   )               (8,304   )
Impairment of intangible assets                                                      -                        (3,196   )               (3,196   )
Impairment of property and equipment                                            (1,061   )                         -                   (1,061   )
Loss from operations before SG&amp;A and other income (expenses)                (1,218   )                    (6,614   )               (7,832   )
Selling, general &amp; administrative                                                                                                 (10,448   )
Loss from operations                                                                                                                  (18,280   )
Net other income                                                                                                                        3,055    
Loss